Once Second Genome identifies lead molecules, the leads will go through very classic drug development processes to further validate in pre-clinical and IND enabling studies. Furthermore, since we identify proteins, peptides and metabolites, we can use standard manufacturing processes to manufacture the therapeutics, which also reduces risk as compared to methods utilizing microbial strains and/or cocktails of strains as the drug. Once the lead is validated in in-life toxicology studies and has been manufactured through standard processes, we expect regulatory approval to be similar to what pharma and biotech are currently used to, which again reduces risk of bringing a novel drug to market.

Second Genome believes strongly in the standards of current drug discovery and development for patients but discovers novel therapeutics by redefining disease through the lens of the interactions between microbiome and human biology.